Amebiasis pp 565-581 | Cite as

Heterocyclic Lead Compounds Against Amebiasis



Amebiasis is a widespread parasitic disease caused by Entamoeba histolytica. This protozoan organism is the third leading parasitic cause of death in the developing world. Nitroimidazole-based drugs such as metronidazole, tinidazole, and ornidazole are the only agents for treating invasive amebiasis, followed by administration with luminal agents. Several side effects in addition to clinical resistance and carcinogenicity to this class of compounds, especially metronidazole, have been observed. Therefore, to combat this neglected protozoan disease it has become essential to discover new leads for the development of novel drugs that are superior or equally effective against E. histolytica but less toxic for humans. Keeping this in mind our group has been making sustained efforts in developing heterocyclic compounds as noble leads because these molecules act as highly functionalized scaffolds. Over a period of a decade hundreds of compounds corresponding to several classes (thiosemicarbazone, metronidazole analogues, azoles, pyrimidines, hydrazones, and triazines) have been synthesized, screened, and evaluated for their antiamoebic activity. In this chapter we discuss the compounds that exhibit new structural scaffolds having antiamoebic activity and elaborate on molecular fragments that play an essential role in improving the activity.


Mannich Base Amebic Liver Abscess Hydrazone Derivative Pyrazoline Derivative Thiadiazole Ring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ralston KS, Petri WA (2011) The ways of a killer: how does Entamoeba histolytica elicit host cell death? Essays Biochem 51:193–210PubMedGoogle Scholar
  2. 2.
    Tengku SA, Norhayati M (2011) Public health and clinical importance of amoebiasis in Malaysia. A review. Trop Biomed 28:194–222PubMedGoogle Scholar
  3. 3.
    Ozum U, Karadaq O, Egilmez R, Engin A, Oztoprak I, Ozcelik S (2008) A case of brain abscess due to Entamoeba species, Eikenella corrodens and Prevotella species. Br J Neurosurg 22:596–598PubMedCrossRefGoogle Scholar
  4. 4.
    Salit IE, Khairnar K, Gough K, Pillai DR (2009) A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain. Clin Infect Dis 49:346–353PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe K, Gatanaga H, Escueta-de Cadiz A, Tanuma J, Nozaki T, Oka S (2011) Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy. PLoS Negl Trop Dis 5:1318CrossRefGoogle Scholar
  6. 6.
    Wu KS, Tsai HC, Lee SS, Liu YC, Wann SR, Wang YH, Mai MH, Chen JK, Sy CL, Chen KM, Chen YJ, Chen YS (2008) Comparison of clinical characteristics of amebic liver abscess in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. J Microbiol Immunol Infect 41:456–461PubMedGoogle Scholar
  7. 7.
    Astelbauer F, Walochnik J (2011) Antiprotozoal compounds: state of the art and new developments. Int J Antimicrob Agents 38:118–124PubMedCrossRefGoogle Scholar
  8. 8.
    Hwang EW, Cheung L, Mojtahed A, Cartwright CA (2011) Relapse of intestinal and hepatic amebiasis after treatment. Dig Dis Sci 56:677–680PubMedCrossRefGoogle Scholar
  9. 9.
    Ordaz-Pichardo C, Shibayama M, Villa-Trevino S, Arriaga-Alba M, Angeles E, de la Garza M (2005) Antiamoebic and toxicity studies of a carbamic acid derivative and its therapeutic effect in a hamster model of hepatic amoebiasis. Antimicrob Agents Chemother 49:1160–1168PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Bendesky A, Menendez D, Ostrosky-Wegman P (2002) Is metronidazole carcinogenic? Mutat Res 511:133–144PubMedCrossRefGoogle Scholar
  11. 11.
    Becker S, Hoffman P, Houpt ER (2011) Efficacy of antiamoebic drugs in a mouse model. Am J Trop Med Hyg 84:581–586PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Beraldo H, Gambino D (2004) The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini Rev Med Chem 4:31–39PubMedCrossRefGoogle Scholar
  13. 13.
    Cerecetto H, Gonzalez M (2008) Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds. Mini Rev Med Chem 8:1355–1383PubMedCrossRefGoogle Scholar
  14. 14.
    Liberta AE, West DX (1992) Antifungal and antitumour activity of heterocyclic thiosemicarbazones and their metal complexes: current status. Biometals 5:121–126PubMedCrossRefGoogle Scholar
  15. 15.
    West DX, Liberta AE, Padhye SB, Chikate RC, Sonawane PB, Kumbhar AS, Yerande RG (1993) Thiosemicarbazone complexes of copper(II): structural and biological studies. Coord Chem Rev 123:49CrossRefGoogle Scholar
  16. 16.
    Quiroga AG, Ranninger CN (2004) Contribution to the SAR field of metallated and coordination complexes: studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs. Coord Chem Rev 248:119–133CrossRefGoogle Scholar
  17. 17.
    Quiroga AG, Perez JM, Montero EI, Masaguer JR, Alonso C, Ranninger CN (1998) Palladated and platinated complexes derived from phenylacetaldehyde thiosemicarbazone with cytotoxic activity in cis-DDP resistant tumor cells. Formation of DNA interstrand cross-links by these complexes. J Inorg Biochem 70:117–123PubMedCrossRefGoogle Scholar
  18. 18.
    Azam A, Agarwal SM (2007) Targeting amoebiasis: status and new developments. Curr Bioactive Comp (Review) 3(2):121–133CrossRefGoogle Scholar
  19. 19.
    Duarte CD, Barreiro EJ, Fraga CA (2007) Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 7:1108–1119PubMedCrossRefGoogle Scholar
  20. 20.
    Shailendra, Bharti N, Naqvi F, Azam A (2003) Synthesis, spectral studies and screening for amoebicidal activity of new palladium (II) complexes derived from thiophene-2-carboxaldehyde thiosemicarbazones. Bioorg Med Chem Lett 13:689–692CrossRefGoogle Scholar
  21. 21.
    Husain K, Abid M, Azam A (2007) Synthesis, characterization and antiamoebic activity of new indole-3-carboxyldehyde thiosemicarbazones and their Pd(II) complexes. Eur J Med Chem 42(10):1300–1308PubMedCrossRefGoogle Scholar
  22. 22.
    Husain K, Bhat AR, Azam A (2008) New Pd(II) complexes of the synthesized 1-N-substituted thiosemicarbazones of 3-indole carboxaldehyde: characterization and antiamoebic assessment against E. histolytica. Eur J Med Chem 43:2016–2028PubMedCrossRefGoogle Scholar
  23. 23.
    Bahl D, Athar F, Soares MB, de Sá MS, Moreira DR, Srivastava RM, Leite AC, Azam A (2010) Structure–activity relationships of mononuclear metal-thiosemicarbazone complexes endowed with potent antiplasmodial and antiamoebic activities. Bioorg Med Chem 18(18):6857–6864PubMedCrossRefGoogle Scholar
  24. 24.
    Bertinaria M, Galli U, Sorba G, Fruttero R, Gasco A, Brenciaglia MI, Scaltrito MM, Dubini F (2003) Synthesis and anti-Helicobacter pylori properties of donor/metronidazole hybrids and related compounds. Drug Dev Res 60:225CrossRefGoogle Scholar
  25. 25.
    Martino GD, Regina GL, Pasquali AD, Ragno R, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artic M, Silvestri R (2005) Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure–activity relationship investigation. J Med Chem 48:4378PubMedCrossRefGoogle Scholar
  26. 26.
    Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA (2003) Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. J Med Chem 46:5533PubMedCrossRefGoogle Scholar
  27. 27.
    Al-Masri AT, Saadeh HA, Mosleh IM, Mubarak MS (2012) Synthesis of new compounds derived from metronidazole and amino acids and their esters as antiparasitic agents. Med Chem Res 21:1700–1707CrossRefGoogle Scholar
  28. 28.
    Keverling JA (1977) In: Arends EJ (ed) Biological activity and chemical structure, vol 21. Elsevier, Amsterdam, p 35Google Scholar
  29. 29.
    Bharti N, Coles SJ, Hursthouse MB, Mayer TA, Gonzalez Garza MT, Cruz-Vega DE, Mata-Cardenas BD, Naqvi F, Maurya MR, Azam A (2002) Synthesis, crystal structure, and enhancement of the efficacy of metronidazole against Entamoeba histolytica by complexation with palladium (II), platinum (II), or copper (II). Helv Chim Acta 85:2704–2712CrossRefGoogle Scholar
  30. 30.
    Athar F, Husain K, Abid M, Agarwal SM, Coles SJ, Hursthouse MB, Maurya MR, Azam A (2005) Synthesis and anti-amoebic activity of gold (I), ruthenium (II), and copper (II) complexes of metronidazole. Chem Biodivers 2:1320–1330PubMedCrossRefGoogle Scholar
  31. 31.
    Abid M, Agarwal SM, Azam A (2008) Synthesis and antiamoebic activity of metronidazole thiosemicarbazone analogues. Eur J Med Chem 43:2035–2039PubMedCrossRefGoogle Scholar
  32. 32.
    Salahuddin A, Agarwal SM, Avecilla F, Azam A (2012) Metronidazole thiosalicylate conjugates: synthesis, crystal structure, docking studies and antiamoebic activity. Bioorg Med Chem Lett 22:5694–5699PubMedCrossRefGoogle Scholar
  33. 33.
    Sammelson RE, Miller RB, Kurth MJ (2000) Linear tetraheterocycles composed of both bidentate diisoxazole and bidentate isoxazole–furyl/thienyl/pyridyl motifs. J Org Chem 65:2225–2228PubMedCrossRefGoogle Scholar
  34. 34.
    Nicolaides DN, Fylaktakidou KC, Litinas KE, Hadjipavlou-Litina D (1996) Synthesis and biological evaluation of some 4-(isoxazolinyl or 1,2,4-oxadiazolyl) coumarins. J Heterocycl Chem 33:967–971CrossRefGoogle Scholar
  35. 35.
    Ryng S, Glowiak T (1998) The isoxazole heterocyclic system: synthesis of a new model structure in immunosuppressing agents. J Chem Crystallogr 28:373–378CrossRefGoogle Scholar
  36. 36.
    Sun Q, Zhang W, Xu J, Cao Y, Wu Q, Zhang D, Liu C, Yu S, Jiang Y (2007) Synthesis and evaluation of novel 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-[(4-substitutedphenyl)-piperazin-1-yl]-propan-2-ols as antifungal agents. Eur J Med Chem 42:1151–1157PubMedCrossRefGoogle Scholar
  37. 37.
    Kerridge D (1988) Antifungal drugs. Drugs Today 24:705–715Google Scholar
  38. 38.
    Koltin Y (1990) Targets for antifungal drug discovery. Annu Rep Med Chem 25:141–148Google Scholar
  39. 39.
    Fromtling RA (1986) Imidazoles as medically important antifungal agents: an overview. Drugs Today 20:235–349Google Scholar
  40. 40.
    Elguero J, Goya P, Jagerovic N, Silva AMS (2002) Pyrazoles as drugs: facts and fantasies, targets in heterocyclic systems, vol 6. Italian Society of Chemistry, Roma, p 52Google Scholar
  41. 41.
    Nauduri D, Reddy GBS (1998) Antibacterial and antimycotics. Part 1. Synthesis and activity of 2-pyrazoline derivatives. Chem Pharm Bull 46:1254–1260PubMedCrossRefGoogle Scholar
  42. 42.
    Abid M, Azam A (2005) 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines: synthesis and in vitro antiamoebic activities. Eur J Med Chem 40:935–942PubMedCrossRefGoogle Scholar
  43. 43.
    Abid M, Azam A (2005) Synthesis and antiamoebic activities of 1-N-substituted cyclised pyrazoline analogues of thiosemicarbazones. Bioorg Med Chem 13:2213–2220PubMedCrossRefGoogle Scholar
  44. 44.
    Abid M, Bhat AR, Athar F, Azam A (2009) Synthesis, spectral studies and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines. Eur J Med Chem 44:417–425PubMedCrossRefGoogle Scholar
  45. 45.
    Husain K, Abid M, Azam A (2008) Novel Pd (II) complexes of 1-N-substituted 3-phenyl-2-pyrazoline derivatives and evaluation of antiamoebic activity. Eur J Med Chem 43:393–403PubMedCrossRefGoogle Scholar
  46. 46.
    Budakoti A, Abid M, Azam A (2006) Synthesis and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3, 5-diphenyl-2-pyrazoline derivatives and their Pd (II) complexes. Eur J Med Chem 41:63–70PubMedCrossRefGoogle Scholar
  47. 47.
    Budakoti A, Abid M, Azam A (2007) Syntheses, characterization and in vitro antiamoebic activity of new Pd (II) complexes with 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives. Eur J Med Chem 42:544–551PubMedCrossRefGoogle Scholar
  48. 48.
    Hayat F, Salahuddin A, Umar S, Azam A (2010) Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail. Eur J Med Chem 45:4669–4675PubMedCrossRefGoogle Scholar
  49. 49.
    Abid M, Azam A (2006) Synthesis, characterization and antiamoebic activity of 1-(thiazolo [4, 5-b] quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives. Bioorg Med Chem Lett 16:2812–2816PubMedCrossRefGoogle Scholar
  50. 50.
    Budakoti A, Bhat AR, Azam A (2008) Synthesis and evaluation of 3-(3-bromo phenyl)-phenyl-1-(thiazolo[4, 5-b] quinoxaline-2-yl)-2-pyrazoline derivatives. Eur J Med Chem 43:1749–1757PubMedCrossRefGoogle Scholar
  51. 51.
    Bhat AR, Athar F, Azam A (2009) Bis-pyrazolines: synthesis, characterization and antiamoebic activity as inhibitors of growth of Entamoeba histolytica. Eur J Med Chem 44:426–431PubMedCrossRefGoogle Scholar
  52. 52.
    Kikuchi M, Ishikawa H, Horimoto H, Tsubouchi H, Shitsuta T, Sasaki H, Itotani M (1997) World Patent WO199732859Google Scholar
  53. 53.
    Matsumoto M, Hasizume H, Tsubouchi H, Sasaki H, Itotani M, Kuroda H, Tomishige T, Kawasaki M, Komatsu M (2007) Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis. Curr Top Med Chem 7:499–507PubMedCrossRefGoogle Scholar
  54. 54.
    Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, Grover G, Harrity T, Ma Z, Moore L, Ren J, Seethala R, Cheng L, Sleph P, Sun W, Tieman A, Wetterau JR, Doweyko A, Chandrasena G, Chang SY, Humphreys WG, Sasseville VG, Biller SA, Ryono DE, Selan F, Hariharan N, Cheng PTW (2005) Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy] phenyl]methyl] glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48:2248–2250PubMedCrossRefGoogle Scholar
  55. 55.
    Bhat AR, Athar F, Azam A (2009) New derivatives of 3, 5-substituted-1, 4, 2-dioxazoles: synthesis and activity against Entamoeba histolytica. Eur J Med Chem 44:926–936PubMedCrossRefGoogle Scholar
  56. 56.
    Wani MY, Athar F, Salauddin A, Agarwal MS, Azam A, Choi I, Bhat AR (2011) Novel terpene based 1, 4, 2-dioxazoles: synthesis, characterization, molecular properties and screening against Entamoeba histolytica. Eur J Med Chem 46:4742–4752CrossRefGoogle Scholar
  57. 57.
    Iqbal PF, Parveen H, Bhat AR, Hayat F, Azam A (2009) Synthesis, characterization, antiamoebic activity and toxicity of novel bisdioxazole derivatives. Eur J Med Chem 44:4747–4751PubMedCrossRefGoogle Scholar
  58. 58.
    Bhopale KK, Pradhan KS, Phaltankar PG, Masani KB, Kaul CL (1993) Activity of a new oxadiazole compound against experimental infection with Entamoeba histolytica and Giardia lamblia in animal models. Ann Tropic Med Parasitol 87:169–178Google Scholar
  59. 59.
    Siddiqui SM, Salahuddin A, Azam A (2013) Mannich base derivatives of 1, 3,4-oxadiazole: synthesis and screening against Entamoeba histolytica. Med Chem Res 22:1313–1319CrossRefGoogle Scholar
  60. 60.
    Rakitin OA (2009) One-pot synthesis of sulfur heterocycles from simple organic substrates. Arkivoc 1:129–149CrossRefGoogle Scholar
  61. 61.
    Clerici F (2002) Thiazole and thiadiazole S-oxide. Adv Heterocycl Chem 83:72–115Google Scholar
  62. 62.
    Serban G, Cuc S, Egri E, Salvan A (2010) Synthesis of some 2-R-5 formyl-1, 3, 4-thiadiazole derivatives by sommelet reaction. Farmacia 58:818–824Google Scholar
  63. 63.
    Ali TES, Kazak AME (2010) Synthesis and antimicrobial activity of some new 1, 3-thiazoles, 1, 3, 4-thiadiazoles, 1, 2, 4-triazoles, and 1, 3-thiazines incorporating acridine and 1, 2, 3, 4-tetrahydroacridine moieties. Eur J Chem 1:6–11CrossRefGoogle Scholar
  64. 64.
    Carvalho SA, Silva EFD, Rita RMS, Castro SLD, Fraga CAM (2004) Synthesis and antitrypanosomal profile of new functionalized 1, 3, 4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg Med Chem Lett 14:5967–5970PubMedCrossRefGoogle Scholar
  65. 65.
    Fardmoghadam MB, Poorrajab F, Kaboudanian S, Emami AS, Shafiee A, Foroumadi A (2008) Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines. Bioorg Med Chem 16:4509–4515CrossRefGoogle Scholar
  66. 66.
    Poorrajab F, Ardestani SK, Emami S, Fardmoghadam MB, Shafiee A, Foroumadi A (2009) Nitroimidazolyl-1, 3, 4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evalution. Eur J Med Chem 44:1758–1762PubMedCrossRefGoogle Scholar
  67. 67.
    Siddiqui SM, Salahuddin A, Azam A (2013) Synthesis of some 1,3,4-thiadiazole derivatives as inhibitors of Entamoeba histolytica. Med Chem Res 22:1305–1312CrossRefGoogle Scholar
  68. 68.
    Hayat F, Salahuddin A, Zargan J, Azam A (2010) Synthesis, characterization, antiamoebic activity and cytotoxicity of novel 2-(quinolin-8-yloxy) acetohydrazones and their cyclized products (1, 2, 3-thiadiazole and 1, 2, 3-selenadiazole derivatives). Eur J Med Chem 45:6127–6134PubMedCrossRefGoogle Scholar
  69. 69.
    Siddiqui SM, Salahuddin A, Azam A (2012) Thiosemicarbazone fragment embedded within 1, 2, 4-triazole ring as inhibitors of Entamoeba histolytica. Bioorg Med Chem Lett 22:2768–2771PubMedCrossRefGoogle Scholar
  70. 70.
    Siddiqui SM, Salahuddin A, Azam A (2012) Synthesis, characterization and antiamoebic activity of some hydrazone and azole derivatives bearing pyridyl moiety as a promising heterocyclic scaffold. Eur J Med Chem 49:411–416PubMedCrossRefGoogle Scholar
  71. 71.
    Gangjee A, Yu J, Kisliuk RL, Haile WH, Sobrero G, McGuire JJ (2003) Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4 ethylpyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents. J Med Chem 46:591–600PubMedCrossRefGoogle Scholar
  72. 72.
    Naimi E, Zhou A, Khalili P, Wiebe LI, Balzarini J, De Clercq E, Knaus EE (2003) Synthesis of 3′- and 5′-nitrooxy pyrimidine nucleoside nitrate esters: “nitric oxide donor” agents for evaluation as anticancer and antiviral agents. J Med Chem 46:995–1004PubMedCrossRefGoogle Scholar
  73. 73.
    Gangjee A, Adair OO, Queener SF (2003) Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J Med Chem 46:5074–5082PubMedCrossRefGoogle Scholar
  74. 74.
    Ismaili L, Nadaradjane A, Nicod L, Guyon C, Xicluna A, Robert J-F, Refouvelet B (2008) Synthesis and antioxidant activity evaluation of new hexahydropyrimido[5,4-c]quinoline-2,5-diones and 2-thioxohexahydropyrimido[5,4-c]quinoline-5-ones obtained by Biginelli reaction in two steps. Eur J Med Chem 43:1270–1275PubMedCrossRefGoogle Scholar
  75. 75.
    Rostom AFS, Fahmy TYH, Saudi NSM (2003) Synthesis and in vitro anti-HIV screening of certain 2-(benzoxazol-2-ylamino)-3H–4-oxopyrimidines. Sci Pharm 71:57–74Google Scholar
  76. 76.
    Parveen H, Hayat F, Mukhtar S, Salahuddin A, Khan A, Islam F, Azam A (2011) Synthesis, characterization and biological evaluation of novel 2, 4, 6-trisubstituted bis-pyrimidine derivatives. Eur J Med Chem 46:4669–4675PubMedCrossRefGoogle Scholar
  77. 77.
    Parveen H, Hayat F, Salahuddin A, Azam A (2010) Synthesis, characterization and biological evaluation of novel 6-ferrocenyl-4-aryl-2-substituted pyrimidine derivatives. Eur J Med Chem 45(8):3497–3503PubMedCrossRefGoogle Scholar
  78. 78.
    Siddiqui SM, Salahuddin A, Azam A (2013) Pyrazolo [3, 4-d] pyrimidine analogues: synthesis, characterization and their in vitro antiamoebic activity. Med Chem Res 22:775–781CrossRefGoogle Scholar
  79. 79.
    Hayat F, Salahuddin A, Azam A (2011) Synthesis, characterization, antiamoebic activity and cytotoxicity of new pyrazolo [3, 4-d] pyrimidine-6-one derivatives. J Enzyme Inhib Med Chem 26:472–479PubMedCrossRefGoogle Scholar
  80. 80.
    Keene AT, Harris A, Phillipson JD, Warhurst DC (1986) In vitro amoebicidal testing of natural products. Part I. Methodology. Planta Med 52:278–285CrossRefGoogle Scholar
  81. 81.
    Hayat F, Moseley E, Salahuddin A, Van Zyl RL, Azam A (2011) Antiprotozoal activity of chloroquinoline based chalcones. Eur J Med Chem 46:1897–1905PubMedCrossRefGoogle Scholar
  82. 82.
    Mushtaque M, Avecilla F, Azam A (2012) Synthesis, characterization and structure optimization of a series of thiazolidinone derivatives as Entamoeba histolytica inhibitors. Eur J Med Chem 55:439–448PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  1. 1.Department of ChemistryJamia Millia IslamiaNew DelhiIndia
  2. 2.Bioinformatics DivisionInstitute of Cytology and Preventive OncologyNoidaIndia

Personalised recommendations